Edition:
United States

China Biologic Products Inc (CBPO.OQ)

CBPO.OQ on NASDAQ Stock Exchange Global Select Market

111.21USD
23 Jan 2017
Change (% chg)

-- (--)
Prev Close
$111.21
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
59,062
52-wk High
$136.50
52-wk Low
$100.53

CBPO.OQ

Chart for CBPO.OQ

About

China Biologic Products, Inc. (China Biologic) is a biopharmaceutical company. The Company is principally engaged in the research, development, manufacturing and sales of human plasma-based biopharmaceutical products in China. It operates in the manufacture and sales of human plasma products segment. It has a product portfolio... (more)

Overall

Beta: 1.78
Market Cap(Mil.): $3,018.00
Shares Outstanding(Mil.): 27.14
Dividend: --
Yield (%): --

Financials

  CBPO.OQ Industry Sector
P/E (TTM): 30.57 44.85 30.38
EPS (TTM): 3.64 -- --
ROI: 29.03 -1.38 14.86
ROE: 23.43 -1.07 16.28

BRIEF-Baillie Gifford & Co reports 5.21 pct passive stake in China Biologic Products

* Baillie Gifford & Co reports 5.21 percent passive stake in China Biologic Products Inc as of december 31 - sec filing Source text : http://bit.ly/2jfbYrf Further company coverage:

Jan 13 2017

BRIEF-China Biologic to build new collection station in Shandong province

* China Biologic to build new collection station and new branch collection facility in Shandong province

Jan 06 2017

BRIEF-China Biologic reports Q3 adj non-gaap earnings per share $1.22

* Raises full year 2016 revenue and adjusted net income forecast

Nov 02 2016

BRIEF-China Biologic acquires full ownership of Guizhou Taibang

* China biologic - Guizhou Taibang has become a wholly owned subsidiary of company

Oct 26 2016

BRIEF-China Biologic receives CFDA clinical trial approval for Human Antithrombin III

* China Biologic receives CFDA clinical trial approval for Human Antithrombin III

Oct 11 2016

BRIEF-China Biologic receives CFDA clinical trial approval for Human Coagulation Factor IX

* China Biologic receives CFDA clinical trial approval for Human Coagulation Factor IX

Sep 19 2016

Earnings vs. Estimates